Logotype for Akari Therapeutics PLC

Akari Therapeutics (AKTX) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Akari Therapeutics PLC

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • Preclinical oncology developer focused on PH1 RNA-splicing-modulating ADCs; AKTX-101 is the lead program, with IND-enabling work aimed at Phase 1 readiness. No product revenue generated.

  • Initiated GLP toxicology studies for TROP2-targeted AKTX-101; a mid-2027 Phase 1 start is planned, subject to additional financing.

  • Q3 2026 net loss was $4.8 million versus $6.4 million a year earlier; nine-month net loss was $24.1 million versus $12.0 million, including $12.1 million of non-cash impairment charges.

  • Preclinical studies showed AKTX-101 activity in urothelial models with limited response or acquired resistance to approved ADCs.

Financial highlights

  • Q3 operating expenses were $4.7 million versus $7.4 million YoY; nine-month operating expenses were $25.0 million versus $14.0 million, primarily reflecting impairment charges.

  • Q3 R&D expense was $2.1 million versus $0.2 million; nine-month R&D was $5.6 million versus $1.7 million, mainly driven by ADC preclinical development.

  • Q3 G&A expense was $2.6 million versus $2.0 million; nine-month G&A was $7.3 million versus $7.1 million, including one-time prior placement-agent termination costs.

  • Operating cash use was $9.8 million for 9M 2026 versus $7.5 million; financing provided $10.4 million, and cash plus restricted cash ended the period at $5.8 million.

Outlook and guidance

  • IND-enabling nonclinical and CMC/manufacturing work, including GLP toxicology and GMP supply, continues toward a planned mid-2027 Phase 1 trial for AKTX-101.

  • Priorities include further resistance-model data, expanding partnerships, and progressing CEACAM5-targeted AKTX-102.

  • Existing cash was expected to fund operations into Q1 2027; additional capital is required, and financing availability, terms, and timing remain uncertain.

  • Future R&D spending depends on funding; potential sources include equity or debt, collaborations, preclinical or clinical funding arrangements, licensing, or asset transactions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Akari Therapeutics